Strides Pharma Science Limited has informed the Exchange regarding a revised press release dated February 05, 2026, titled "Strides Pharma Inc receives USFDA closure report (EIR) for its formulations facility at Chestnut Ridge, New YorkInspection included Drug Device Combinations covering our recent filing in Nasal Sprays domain".
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Strides Pharma Science has issued a revised version of its February 5, 2026 press release. The original release announced that its US subsidiary, Strides Pharma Inc, has received the USFDA Establishment Inspection Report (EIR) for its formulations plant in Chestnut Ridge, New York. An EIR means the US drug regulator has officially closed its inspection of the facility with no further action required. The inspection also covered Drug Device Combination products, including the company's recent filing in the nasal sprays segment. Receiving an EIR clears the path for the facility to continue supplying the US market and to launch the new nasal spray product.
Positive for shareholders — the EIR removes regulatory overhang on the New York facility and validates the company's entry into the higher-margin nasal sprays and drug-device combination segments in the US market, which is Strides' biggest revenue geography.